Asian Spine J.  2015 Jun;9(3):338-343. 10.4184/asj.2015.9.3.338.

The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis

• Inage K
• Orita S
• Yamauchi K
• Sakuma Y
• Kubota G
• Oikawa Y
• Sainoh T
• Sato J
• Fujimoto K
• Shiga Y
• Takahashi
• Ohtori S

• KMID: 2270132
• DOI: http://doi.org/10.4184/asj.2015.9.3.338

Abstract

STUDY DESIGN: Retrospective study. PURPOSE: We conducted a study to investigate the time course changes in bone metabolic markers after the administration of the anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody and to assess drug compliance among osteoporotic patients. OVERVIEW OF LITERATURE: The anti-RANKL antibody is expected to provide an improvement in those with a bone metabolism disorder. However there are only a few clinical reports available on the effect of treatment.
METHODS
We included 40 post-menopausal osteoporotic patients who received the anti-RANKL antibody. To determine the time course changes in the bone metabolic markers, we measured the serum tartrate-resistant acid phosphatase 5b (TRACP 5b; a bone resorption marker) and the serum N-terminal propeptide of type 1 collagen (P1NP; a bone formation marker) levels prior to and 1 month after administrating the anti-RANKL antibody. To evaluable drug compliance, we assessed the dropout rate during treatment and at 6 months after treatment.
RESULTS
The average TRACP 5b level significantly decreased from 574.8 mU/dL before treatment to 153.2 mU/dL 1 month after treatment (p<0.05). There was no significant difference in the average P1NP level, which was 56.9 microG/L and 35.1 microG/L before and 1 month after treatment, respectively (p>0.05). As for drug compliance, we did not have any dropouts during the treatment or after 6 months (dropout rate: 0%).
CONCLUSIONS
Our study suggests that anti-RANKL antibody treatment suppresses bone resorption and maintains bone formation.

Keyword

Tartrate-resistant acid phosphatase; Receptor activator of nuclear factor-kappa B ligand

MeSH Terms

Acid Phosphatase
Bone Resorption
Collagen Type I
Compliance*
Humans
Metabolism
Osteogenesis
Osteoporosis*
Patient Dropouts
RANK Ligand
Retrospective Studies
Acid Phosphatase
Collagen Type I
RANK Ligand